Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder

被引:221
|
作者
Robinson, DG [1 ]
Woerner, MG
Alvir, JMJ
Bilder, RM
Hinrichsen, GA
Lieberman, JA
机构
[1] Hillside Hosp, N Shore Long Isl Jewish Hlth Syst, Dept Psychiat Res, Glen Oaks, NY 11004 USA
[2] Albert Einstein Coll Med, Bronx, NY 10467 USA
[3] Nathan S Kline Inst Psychiat Res, Orangeburg, NY 10962 USA
[4] Hillside Hosp, N Shore Long Isl Jewish Hlth Syst, Dept Psychol Serv, Glen Oaks, NY 11004 USA
[5] Hillside Hosp, N Shore Long Isl Jewish Hlth Syst, Div Geriatr Psychiat, Glen Oaks, NY 11004 USA
[6] Univ N Carolina, Chapel Hill, NC 27515 USA
关键词
antipsychotic agents; cognition; neuropsychological tests; patient compliance; schizophrenia;
D O I
10.1016/S0920-9964(01)00312-7
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: Enhancing medication adherence early in the course of schizophrenia and schizoaffective disorder may substantially improve long-term course. Although extensively studied in multi-episode patients, little data exist on medication adherence by first-episode patients. Method: Medication adherence was assessed during the first year of treatment and following recovery from the first relapse in patients treated by a standardized medication algorithm. Results: During the first year of treatment, patients with poorer premorbid cognitive functioning were more likely to stop antipsychotics (t = -2.54, df= 75, p = 0.01). Parkinsonian side effects increased the likelihood (hazard ratio=41.22; 95% CI= 2.30, 737.89; p=0.01), and better executive function decreased the likelihood (hazard ratio = 0.40; 95% Cl = 0.18, 0.88; p = 0.02) that patients discontinued maintenance medication after a first relapse. Conclusion: Interventions to ameliorate cognitive deficits and Parkinsonian side effects may enhance treatment adherence. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:209 / 219
页数:11
相关论文
共 50 条
  • [1] Predictors of noncompliance in males with first-episode schizophrenia, schizophreniform and schizoaffective disorder
    Novak-Grubic, V
    Tavcar, R
    EUROPEAN PSYCHIATRY, 2002, 17 (03) : 148 - 154
  • [2] Social cognition in first-episode schizophrenia/schizoaffective disorder patients
    Fortuny, Judit Joseph
    Navarra-Ventura, Guillem
    Fernandez-Gonzaloa, Sol
    Tomas, Esther Pousa
    Armengol, Josep Maria Crosas
    Vidal, Diego Palao
    Vicente, Merce Jodar
    SPANISH JOURNAL OF PSYCHIATRY AND MENTAL HEALTH, 2023, 16 (03): : 169 - 174
  • [3] Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder
    Sevy, S
    Robinson, DG
    Solloway, S
    Alvir, JM
    Woerner, MG
    Bilder, R
    Goldman, R
    Lieberman, J
    Kane, J
    ACTA PSYCHIATRICA SCANDINAVICA, 2001, 104 (05) : 367 - 374
  • [4] First-episode schizophrenia, schizophreniform disorder and schizoaffective psychosis: Baseline clinical severity and predictors
    Simonsen, E
    Haahr, U
    Friis, S
    Melle, I
    Larsen, TK
    Vaglum, P
    McGlashan, TH
    SCHIZOPHRENIA RESEARCH, 1999, 36 (1-3) : 349 - 349
  • [5] Predictors of poor adherence to medication among patients with first-episode schizophrenia-spectrum disorder
    Le Quach, Phuong
    Mors, Ole
    Christensen, Torben Ostergaard
    Krarup, Gertrud
    Jorgensen, Per
    Bertelsen, Mette
    Jeppesen, Pia
    Petersen, Lone
    Thorup, Anne
    Nordentoft, Merete
    EARLY INTERVENTION IN PSYCHIATRY, 2009, 3 (01) : 66 - 74
  • [6] Predictors of recovery from a first episode of schizophrenia or schizoaffective disorder
    Robinson, DG
    Woerner, MG
    Alvir, JM
    Bilder, RM
    Lieberman, JA
    SCHIZOPHRENIA RESEARCH, 2001, 49 (1-2) : 243 - 243
  • [7] Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders
    Perkins, DO
    Lieberman, JA
    Gu, HB
    Tohen, M
    McEvoy, J
    Green, AI
    Zipursky, RB
    Strakowski, SM
    Sharma, T
    Kahn, RS
    Gur, R
    Tollefson, G
    BRITISH JOURNAL OF PSYCHIATRY, 2004, 185 : 18 - 24
  • [8] A trial of low doses of risperidone in the treatment of patients with first-episode schizophrenia, schizophreniform disorder, or schizoaffective disorder
    Huq, ZU
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2004, 24 (02) : 220 - 224
  • [9] Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder
    Robinson, DG
    Woerner, MG
    Alvir, JMJ
    Geisler, S
    Koreen, A
    Sheitman, B
    Chakos, M
    Mayerhoff, D
    Bilder, R
    Goldman, R
    Lieberman, JA
    AMERICAN JOURNAL OF PSYCHIATRY, 1999, 156 (04): : 544 - 549
  • [10] Suicidality in schizophrenia, delusional disorder, schizoaffective disorder and first-episode of psychosis: a systematic review
    Alvarez Pedrero, A.
    Guardia Delgado, A.
    Gonzalez-Rodriguez, A.
    Betriu, M.
    Parra, I.
    Monreal, J. A.
    Palao Vidal, D.
    Labad, J.
    EUROPEAN PSYCHIATRY, 2020, 63 : S577 - S578